MUNICH, Germany, Sept. 29 Nomad Bioscience GmbH announcesthat it entered into a broad licensing agreement with Bayer Innovation GmbHand Icon Genetics group. It provides Nomad access to Icon's proprietarytechnology platforms, including its transient expression technologymagnICON(R), for manufacturing biomaterials and selected biosimilarpharmaceutical proteins in green plants. The agreement provides Nomad with astrategically needed freedom to operate in its core business areas. Thefinancial terms of the agreement are not disclosed.
"Icon Genetics' proprietary gene transfer systems provide a broad solutionto the upstream part of manufacturing, and combined with Nomad downstreamtechnologies, they should result in a superior fully integrated process formost of our intended product candidates," said Dr. Yuri Gleba, the founder ofNomad Bioscience. Prof. Dr. Gleba is also co-inventor of Icon's technologiesas well as co-founder and managing director of Icon Genetics.
"Icon has developed new generation production platforms that are by farmore effective than those commercialized today. Since our own strategic focusis on proprietary biopharmaceuticals, we were looking for a partner who couldbest apply our proprietary expression methods to other new classes ofproducts," said Dr. Detlef Wollweber, Managing Director of Bayer Innovation.
About Nomad Bioscience:
Nomad Bioscience, headquartered in Munich, is a private start-upbiotechnology company developing a series of high value materials such asnanopatterned materials, protein scaffolds, proteins and enzymes for importantmarkets including biosimilar biopharmaceuticals, electric batteries andbiofuels.
SOURCE Nomad Bioscience GmbH